MAPS-2 Study

The Metoclopramide for Avoiding Pneumonia after Stroke (MAPS-2) Trial: a single-blind, randomized controlled trial of metoclopramide for the prevention of pneumonia in patients with dysphagia after an acute stroke

The MAPS-2 study is back! Since the last version we had to drop the selective oral decontamination arm. The new MAPS-2 study tests whether giving metoclopramide 10 mg three times a day for 14 days prevents pneumonia and death after acute stroke. We will recruit patients from over 60 hospitals in the UK.

Please click MAPS-2 for a protocol summary, the expressioin of interest form, a list of collaborating centres, the study team, and our newsletters.